Bioactive Wound Care Market Expected to Reach USD 4.9 Billion By 2020

The Bioactive Wound Care market can be segmented on the basis of the different modes of interaction and by region. The different interaction modes include First-Line Interactive Dressing, consisting of Semi-Permeable Films, Foams, Alginates and others, and Second-Line Interactive Dressing which involves Honey, Hydrofiber, Silicone and Silver. By region, the market can be classified into North America, Europe, APAC and RoW regions.
Rapid Technological Innovations Will Accelerate the Growth of Bioactive Wound Care Market to 4.9 USD Billion By 2020.

According to the market research report, “Bioactive Wound Care Market Analysis: By First Line Interactive Dressing (Foams, Alginates, Hydrogel, Hydrocolloids, Collagen); By Second Line Interactive Dressing (Honey, Hydrofiber, Silicon, Silver) – With Forecast (2015 – 2020)”, the bioactive wound care market is projected to grow to $4.9 Billion by 2020 at high CAGR.

Browse 13 Market Tables, 52 Figures spread through 124 Pages and an in-depth TOC on “Bioactive Wound Care Market”

Normal wound healing processes are ineffective in treating full-thickness acute burn injuries and other chronic wounds such as venous ulcers, pressure ulcers, and diabetic foot ulcers. The advent of bioactive wound dressing technology aims at improving the healing power in these conditions. Bioactive dressings combat microbial infections, thereby controlling infection and fastening the healing process. Besides being cost-effective, the bioactive wound dressings also reduce leakage, pain and odor resulting from the wounds. Bioactive wound care dressings involve different materials like alginates, chitosan, keratin, collagens and hydrocolloids, which take active participation in healing wounds and fighting infections, rather than just shielding wounds from the outside environment. Bioactive Wound care is a very niche market but is estimated to flourish during the forecast period, owing to the increased demand from the patient pool all across the globe.

Wound Care market has become one of the prominent sectors in Healthcare industry with market cap of $15 billion in 2014. The bioactive wound care market is still in the nascent stage with a huge opportunity to take over traditional wound care market. The primary objective of bioactive wound dressings is to reduce the treatment time which will save the overall cost for the patient. The relevance of bioactive wound dressings has increased over the years due to the proven efficacy of its positive effect on wound healing process.

According to recent report by IndustryARC, the global bioactive wound care market will grow at CAGR of 5.56% and reach USD 4.9 Billion by 2020. The market for Silver dressings will be the major contributor in this growth. The demand for honey dressings will be relatively low due to the high uptake of better bioactive wound dressings such as alginate dressings and foam dressings.

Make an Inquiry @

North America accounts for the maximum revenue share in the fiscal year ended 2015, followed by Europe and Asia-pacific regions and will continue to be the leading region in Bioactive Wound Care market during the forecast period till 2020. This can be attributed to the higher incidence of chronic and acute wounds as well as the various government healthcare reimbursement policies which further aid in such treatments. Increasing geriatric population in countries such as U.S. and Canada is also one of the major driving factors behind the growth of Bioactive Wound Care market across these regions.

The market will slowly expand in Middle East owing to increasing disposable income and effective price control regulations. The primary beneficiary of bioactive wound dressings are the people affected with diabetes, venous leg ulcers and burns. First-Line Interactive Dressing mode of interaction is the most prominent because this treatment process is affordable and treats a varied range of wounds, whereas the Second-Line Interactive Dressing mode is expensive and has specific dressings for specific kind of wounds. The increasing use of stem cells and growth factors will help in further diversification of the market.

Silver Dressing: Proving the Efficacy Through Clinical Trials

According to statistics, 25% the diabetic population is prone to developing diabetic foot ulcers in their lifetime. This gave rise to the introduction of bioactive wound dressings in the late 1980’s and they continue to serve patients worldwide. While the earlier dressings included hydrocolloids, honey and semi-permeable films; the focus slowly shifted towards silver.

Silver dressings are being manufactured and used to treat chronic and acute wounds with companies such as Smith & Nephew plc, 3M Healthcare and Convatec Inc. leading from the front. Silver dressings are known to be expensive as compared to other bioactive wound dressings. It is important to understand the cost-benefit relationship for silver dressings and is the high price justified. Silver is known to have antimicrobial properties and the earliest example is of using silver sulphadiazine cream (SDC) to treat burns. Unfortunately, the cream was not able to solve the purpose completely and thus went out of the market.

Today, the silver dressings are being used across North America and Europe. However, to prove that silver dressings are better than other dressings and there is strong benefit associated with its use, there is a need of ‘Gold Standard’ proof. There is a need for randomized trial which can demonstrate the positive effect of silver dressings based on certain parameters such as healing time and percentage healing achieved. These trials should be conducted across different type of wounds these dressings intend to heal. The time duration is another important consideration. While some wounds may heal slowly and some may heal faster, the trial should be conducted for at least 12 weeks in the case of chronic wounds.

Theoretically, these dressings are able to heal wounds faster and contain antimicrobial properties, but there have been few trials to validate the theory. Silver dressings are being used like never before with clinical efficacy still falling short. The physicians need to understand and make accurate diagnosis to prescribe silver dressings. Silver dressings currently exist in the market and they will continue to remain

The major companies in the market are:

  • 3M Healthcare
  • Smith & Nephew plc
  • Convatec Inc.
  • Covidien
  • Acelity, Inc.

Avail PDF Sample @

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Sanjay Matthews
Email: Send Email
Phone: 1-614-588-8538 (Ext: 101)
Country: United States